HK Stock MarketDetailed Quotes

TATA HEALTH (01255)

Watchlist
  • 1.800
  • 0.0000.00%
Market Closed Apr 30 11:41 CST
437.12MMarket Cap32.73P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

TATA HEALTH (01255) Income Statement

All
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2025
(Q6)Jun 30, 2025
(FY)Dec 31, 2024
(Q6)Jun 30, 2024
(FY)Dec 31, 2023
(Q6)Jun 30, 2023
(FY)Dec 31, 2022
(Q6)Jun 30, 2022
(FY)Dec 31, 2021
(Q6)Jun 30, 2021
Turnover
-23.04%99.8M
-41.75%42.12M
-37.52%129.68M
-30.56%72.31M
43.52%207.54M
63.94%104.13M
-10.14%144.61M
-13.13%63.52M
3.58%160.93M
-7.56%73.12M
Operating income
-23.04%99.8M
-41.75%42.12M
-37.52%129.68M
-30.56%72.31M
43.52%207.54M
63.94%104.13M
-10.14%144.61M
-13.13%63.52M
3.58%160.93M
-7.56%73.12M
Cost of sales
50.55%-19.54M
56.92%-7.29M
30.42%-39.51M
10.51%-16.91M
-85.18%-56.78M
-72.32%-18.9M
45.45%-30.66M
62.20%-10.97M
53.58%-56.21M
57.31%-29.01M
Operating expenses
50.55%-19.54M
56.92%-7.29M
30.42%-39.51M
10.51%-16.91M
-85.18%-56.78M
-72.32%-18.9M
45.45%-30.66M
62.20%-10.97M
53.58%-56.21M
57.31%-29.01M
Gross profit
-10.99%80.26M
-37.12%34.83M
-40.19%90.17M
-35.01%55.4M
32.31%150.76M
62.20%85.23M
8.81%113.94M
19.15%52.55M
205.45%104.72M
296.24%44.1M
Selling expenses
14.89%-55.72M
24.66%-18.71M
18.57%-65.47M
33.78%-24.84M
-30.12%-80.4M
-29.85%-37.51M
5.91%-61.79M
-2.30%-28.89M
19.96%-65.67M
30.34%-28.24M
Administrative expenses
20.49%-47.36M
-18.84%-37.3M
40.73%-59.57M
49.36%-31.39M
-19.88%-100.5M
-55.25%-61.99M
13.80%-83.84M
17.00%-39.93M
3.77%-97.26M
10.10%-48.1M
Impairment and provision
85.03%-4M
----
-137.37%-26.73M
----
-675.41%-11.26M
----
85.04%-1.45M
---48K
74.81%-9.71M
----
-Other impairment is provision
85.03%-4M
----
-137.37%-26.73M
----
-675.41%-11.26M
----
85.04%-1.45M
---48K
74.81%-9.71M
----
Special items of operating profit
2,092.14%43.61M
1,501.56%43.11M
-127.66%-2.19M
-394.92%-3.08M
-79.46%7.91M
-96.98%1.04M
1,732.83%38.53M
1,678.66%34.51M
-87.97%2.1M
-55.46%1.94M
Operating profit
126.32%16.79M
661.39%21.93M
-90.48%-63.78M
70.45%-3.91M
-721.15%-33.49M
-172.66%-13.22M
108.19%5.39M
160.04%18.19M
61.26%-65.81M
67.71%-30.3M
Financing cost
34.13%-2.8M
-8.82%-1.33M
-146.40%-4.25M
-14.29%-1.22M
30.87%-1.72M
1.47%-1.07M
9.54%-2.49M
-129.32%-1.09M
22.77%-2.76M
---474K
Share of profits of associates
----
----
----
----
47.50%-210K
----
30.19%-400K
54.60%-400K
-173.46%-573K
---881K
Earning before tax
120.56%13.99M
501.48%20.6M
-92.07%-68.03M
64.10%-5.13M
-1,518.50%-35.42M
-185.54%-14.29M
103.61%2.5M
152.78%16.71M
59.96%-69.14M
66.26%-31.65M
Tax
-107.49%-637K
----
50.96%-307K
----
30.29%-626K
----
31.50%-898K
----
-231.06%-1.31M
----
After-tax profit from continuing operations
119.54%13.35M
501.48%20.6M
-89.59%-68.34M
64.10%-5.13M
-2,354.28%-36.05M
-185.54%-14.29M
102.27%1.6M
152.78%16.71M
59.29%-70.45M
66.86%-31.65M
Earning after tax
119.54%13.35M
501.48%20.6M
-89.59%-68.34M
64.10%-5.13M
-2,354.28%-36.05M
-185.54%-14.29M
102.27%1.6M
152.78%16.71M
59.29%-70.45M
66.86%-31.65M
Minority profit
----
----
----
----
41.81%-3.75M
43.32%-1.96M
33.48%-6.45M
24.24%-3.46M
54.30%-9.69M
55.56%-4.57M
Profit attributable to shareholders
119.54%13.35M
501.48%20.6M
-111.61%-68.34M
58.38%-5.13M
-501.32%-32.29M
-161.12%-12.33M
113.24%8.05M
174.47%20.17M
59.99%-60.76M
68.23%-27.08M
Basic earnings per share
117.86%0.05
500.00%0.08
-115.38%-0.28
60.00%-0.02
-533.33%-0.13
-162.50%-0.05
111.54%0.03
166.67%0.08
63.38%-0.26
69.85%-0.12
Diluted earnings per share
117.86%0.05
500.00%0.08
-115.38%-0.28
60.00%-0.02
-533.33%-0.13
-162.50%-0.05
111.54%0.03
166.67%0.08
63.38%-0.26
69.85%-0.12
Currency Unit
HKD
HKD
HKD
HKD
HKD
HKD
HKD
HKD
HKD
HKD
Accounting Standards
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
Auditor
--
--
--
--
--
--
National Health Accounting Firm Co., Ltd.
--
National Health Accounting Firm Co., Ltd.
--
(FY)Dec 31, 2025(Q6)Jun 30, 2025(FY)Dec 31, 2024(Q6)Jun 30, 2024(FY)Dec 31, 2023(Q6)Jun 30, 2023(FY)Dec 31, 2022(Q6)Jun 30, 2022(FY)Dec 31, 2021(Q6)Jun 30, 2021
Turnover -23.04%99.8M-41.75%42.12M-37.52%129.68M-30.56%72.31M43.52%207.54M63.94%104.13M-10.14%144.61M-13.13%63.52M3.58%160.93M-7.56%73.12M
Operating income -23.04%99.8M-41.75%42.12M-37.52%129.68M-30.56%72.31M43.52%207.54M63.94%104.13M-10.14%144.61M-13.13%63.52M3.58%160.93M-7.56%73.12M
Cost of sales 50.55%-19.54M56.92%-7.29M30.42%-39.51M10.51%-16.91M-85.18%-56.78M-72.32%-18.9M45.45%-30.66M62.20%-10.97M53.58%-56.21M57.31%-29.01M
Operating expenses 50.55%-19.54M56.92%-7.29M30.42%-39.51M10.51%-16.91M-85.18%-56.78M-72.32%-18.9M45.45%-30.66M62.20%-10.97M53.58%-56.21M57.31%-29.01M
Gross profit -10.99%80.26M-37.12%34.83M-40.19%90.17M-35.01%55.4M32.31%150.76M62.20%85.23M8.81%113.94M19.15%52.55M205.45%104.72M296.24%44.1M
Selling expenses 14.89%-55.72M24.66%-18.71M18.57%-65.47M33.78%-24.84M-30.12%-80.4M-29.85%-37.51M5.91%-61.79M-2.30%-28.89M19.96%-65.67M30.34%-28.24M
Administrative expenses 20.49%-47.36M-18.84%-37.3M40.73%-59.57M49.36%-31.39M-19.88%-100.5M-55.25%-61.99M13.80%-83.84M17.00%-39.93M3.77%-97.26M10.10%-48.1M
Impairment and provision 85.03%-4M-----137.37%-26.73M-----675.41%-11.26M----85.04%-1.45M---48K74.81%-9.71M----
-Other impairment is provision 85.03%-4M-----137.37%-26.73M-----675.41%-11.26M----85.04%-1.45M---48K74.81%-9.71M----
Special items of operating profit 2,092.14%43.61M1,501.56%43.11M-127.66%-2.19M-394.92%-3.08M-79.46%7.91M-96.98%1.04M1,732.83%38.53M1,678.66%34.51M-87.97%2.1M-55.46%1.94M
Operating profit 126.32%16.79M661.39%21.93M-90.48%-63.78M70.45%-3.91M-721.15%-33.49M-172.66%-13.22M108.19%5.39M160.04%18.19M61.26%-65.81M67.71%-30.3M
Financing cost 34.13%-2.8M-8.82%-1.33M-146.40%-4.25M-14.29%-1.22M30.87%-1.72M1.47%-1.07M9.54%-2.49M-129.32%-1.09M22.77%-2.76M---474K
Share of profits of associates ----------------47.50%-210K----30.19%-400K54.60%-400K-173.46%-573K---881K
Earning before tax 120.56%13.99M501.48%20.6M-92.07%-68.03M64.10%-5.13M-1,518.50%-35.42M-185.54%-14.29M103.61%2.5M152.78%16.71M59.96%-69.14M66.26%-31.65M
Tax -107.49%-637K----50.96%-307K----30.29%-626K----31.50%-898K-----231.06%-1.31M----
After-tax profit from continuing operations 119.54%13.35M501.48%20.6M-89.59%-68.34M64.10%-5.13M-2,354.28%-36.05M-185.54%-14.29M102.27%1.6M152.78%16.71M59.29%-70.45M66.86%-31.65M
Earning after tax 119.54%13.35M501.48%20.6M-89.59%-68.34M64.10%-5.13M-2,354.28%-36.05M-185.54%-14.29M102.27%1.6M152.78%16.71M59.29%-70.45M66.86%-31.65M
Minority profit ----------------41.81%-3.75M43.32%-1.96M33.48%-6.45M24.24%-3.46M54.30%-9.69M55.56%-4.57M
Profit attributable to shareholders 119.54%13.35M501.48%20.6M-111.61%-68.34M58.38%-5.13M-501.32%-32.29M-161.12%-12.33M113.24%8.05M174.47%20.17M59.99%-60.76M68.23%-27.08M
Basic earnings per share 117.86%0.05500.00%0.08-115.38%-0.2860.00%-0.02-533.33%-0.13-162.50%-0.05111.54%0.03166.67%0.0863.38%-0.2669.85%-0.12
Diluted earnings per share 117.86%0.05500.00%0.08-115.38%-0.2860.00%-0.02-533.33%-0.13-162.50%-0.05111.54%0.03166.67%0.0863.38%-0.2669.85%-0.12
Currency Unit HKDHKDHKDHKDHKDHKDHKDHKDHKDHKD
Accounting Standards HKASHKASHKASHKASHKASHKASHKASHKASHKASHKAS
Auditor ------------National Health Accounting Firm Co., Ltd.--National Health Accounting Firm Co., Ltd.--

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Market Insights
Petroleum
No. Symbol 20D % Chg
Sample Name
Sample Code
 +7.99%
Sample Name
Sample Code
 +4.00%
Sample Name
Sample Code
 +2.86%
4
SINOPEC CORP
00386
+2.22%
5
CNOOC
00883
+1.66%
View More
No. Symbol 20D % Chg
Sample Name
Sample Code
 +46.25%
Sample Name
Sample Code
 +33.47%
Sample Name
Sample Code
 +26.48%
4
Loongson Technology Corporation
688047
+24.63%
5
Rockchip Electronics
603893
+19.54%
View More
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"

- No more -